Algeta and Ablynx collaborate to discover and develop targeted cancer therapies.
作者信息
King Gemma
出版信息
Future Med Chem. 2013 Feb;5(2):123.
PMID:23476969
Abstract
摘要
相似文献
1
Algeta and Ablynx collaborate to discover and develop targeted cancer therapies.
Future Med Chem. 2013 Feb;5(2):123.
2
Grants4Targets: an open innovation initiative to foster drug discovery collaborations.
Nat Rev Drug Discov. 2015 Jan;14(1):74-6. doi: 10.1038/nrd3078-c2. Epub 2014 Nov 28.
3
Academia-industry alliance: Belfer Institute and sanofi-aventis collaborate to develop new cancer therapeutics.
Dis Model Mech. 2010 Nov-Dec;3(11-12):669. doi: 10.1242/dmm.007054.
4
The long march of antisense.
Nat Rev Drug Discov. 2011 Jun;10(6):401-2. doi: 10.1038/nrd3474.
5
The future is much closer collaboration between the pharmaceutical industry and academic medical centers.
Clin Pharmacol Ther. 2010 May;87(5):525-7. doi: 10.1038/clpt.2010.29.
6
Deal watch: MSD buys in to emerging epigenetic cancer target.
Nat Rev Drug Discov. 2016 Mar;15(3):153. doi: 10.1038/nrd.2016.20.
7
Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.
J Med Chem. 2012 May 24;55(10):4527-38. doi: 10.1021/jm201649s. Epub 2012 Mar 23.
8
An accelerated pathway for targeted cancer therapies.
Nat Rev Drug Discov. 2011 Feb;10(2):79-80. doi: 10.1038/nrd3360.
9
Biomedicine. Pharma firms push for sharing of cancer trial data.
Science. 2012 Oct 5;338(6103):29. doi: 10.1126/science.338.6103.29.
10
Cancer nanotechnology: small, but heading for the big time.
Nat Rev Drug Discov. 2007 Mar;6(3):174-5. doi: 10.1038/nrd2285.
Zotero 插件